<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Molecules</journal-id><journal-id journal-id-type="iso-abbrev">Molecules</journal-id><journal-id journal-id-type="publisher-id">molecules</journal-id><journal-title-group><journal-title>Molecules</journal-title></journal-title-group><issn pub-type="epub">1420-3049</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.3390/molecules24142603</article-id><article-id pub-id-type="publisher-id">molecules-24-02603</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Design, Synthesis, and Biological Evaluation of EdAP, a 4&#x02032;-Ethynyl-2&#x02032;-Deoxyadenosine 5&#x02032;-Monophosphate Analog, as a Potent Influenza a Inhibitor</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Takeuchi</surname><given-names>Toshifumi</given-names></name><xref ref-type="aff" rid="af1-molecules-24-02603">1</xref><xref rid="c1-molecules-24-02603" ref-type="corresp">*</xref><xref ref-type="author-notes" rid="fn1-molecules-24-02603">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Sriwilaijaroen</surname><given-names>Nongluk</given-names></name><xref ref-type="aff" rid="af2-molecules-24-02603">2</xref><xref ref-type="aff" rid="af3-molecules-24-02603">3</xref><xref ref-type="author-notes" rid="fn1-molecules-24-02603">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Sakuraba</surname><given-names>Ayako</given-names></name><xref ref-type="aff" rid="af1-molecules-24-02603">1</xref></contrib><contrib contrib-type="author"><name><surname>Hayashi</surname><given-names>Ei</given-names></name><xref ref-type="aff" rid="af1-molecules-24-02603">1</xref></contrib><contrib contrib-type="author"><name><surname>Kamisuki</surname><given-names>Shinji</given-names></name><xref ref-type="aff" rid="af4-molecules-24-02603">4</xref></contrib><contrib contrib-type="author"><name><surname>Suzuki</surname><given-names>Yasuo</given-names></name><xref ref-type="aff" rid="af3-molecules-24-02603">3</xref></contrib><contrib contrib-type="author"><name><surname>Ohrui</surname><given-names>Hiroshi</given-names></name><xref ref-type="aff" rid="af5-molecules-24-02603">5</xref></contrib><contrib contrib-type="author"><name><surname>Sugawara</surname><given-names>Fumio</given-names></name><xref ref-type="aff" rid="af1-molecules-24-02603">1</xref></contrib></contrib-group><aff id="af1-molecules-24-02603"><label>1</label>Department of Applied Biological Science, Faculty of Science and Technology, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan</aff><aff id="af2-molecules-24-02603"><label>2</label>Department of Preclinical Sciences, Faculty of Medicine, Thammasat University, Pathumthani 12120, Thailand</aff><aff id="af3-molecules-24-02603"><label>3</label>Health Science Hills, College of Life and Health Sciences, Chubu University, Kasugai, Aichi 487-8501, Japan</aff><aff id="af4-molecules-24-02603"><label>4</label>School of Veterinary Medicine, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara, Kanagawa 252-5201, Japan</aff><aff id="af5-molecules-24-02603"><label>5</label>Yokohama University of Pharmacy, Matano-cho 601, Totsuka-ku, Yokohama, Kanagawa 245-0066, Japan</aff><author-notes><corresp id="c1-molecules-24-02603"><label>*</label>Correspondence: <email>takeuchit@bikaken.or.jp</email></corresp><fn id="fn1-molecules-24-02603"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>17</day><month>7</month><year>2019</year></pub-date><pub-date pub-type="collection"><month>7</month><year>2019</year></pub-date><volume>24</volume><issue>14</issue><elocation-id>2603</elocation-id><history><date date-type="received"><day>20</day><month>6</month><year>2019</year></date><date date-type="accepted"><day>16</day><month>7</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 by the authors.</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Influenza A viruses leading to infectious respiratory diseases cause seasonal epidemics and sometimes periodic global pandemics. Viral polymerase is an attractive target in inhibiting viral replication, and 4&#x02032;-ethynyladenosine, which has been reported as a highly potent anti-human immunodeficiency virus (HIV) nucleoside derivative, can work as an anti-influenza agent. Herein, we designed and synthesized a 4&#x02032;-ethynyl-2&#x02032;-deoxyadenosine 5&#x02032;-monophosphate analog called EdAP (<bold>5</bold>). EdAP exhibited potent inhibition against influenza virus multiplication in Madin&#x02013;Darby canine kidney (MDCK) cells transfected with human &#x003b1;2-6-sialyltransferase (SIAT1) cDNA and did not show any toxicity toward the cells. Surprisingly, this DNA-type nucleic acid analog (<bold>5</bold>) inhibited the multiplication of influenza A virus, although influenza virus is an RNA virus that does not generate DNA.</p></abstract><kwd-group><kwd>4&#x02032;-ethynyl-2&#x02032;-deoxyadenosine 5&#x02032;-monophosphate</kwd><kwd>influenza</kwd><kwd>anti-influenza activity</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-molecules-24-02603"><title>1. Introduction</title><p>Influenza caused by influenza A virus is an infectious respiratory disease, which is responsible for seasonal epidemics and periodic global pandemics. This infection causes mild to severe illness, including death, in persons with an increased risk for severe diseases, including the elderly, infants, and the ill, resulting in three to five million severe cases and 250,000 to 500,000 deaths worldwide [<xref rid="B1-molecules-24-02603" ref-type="bibr">1</xref>]. The most efficient prevention method in healthy adults is vaccination. However, for the elderly, vaccination may be less efficient and may increase complications and death. Four classes of antiviral medicines are currently available. These include (i) the neuraminidase inhibitors oseltamivir (Roche), zanamivir (GlaxoSmithKline), peramivir (BioCryst Pharmaceuticals), and laninamivir octanoate (Daiichi Sankyo); (ii) the M2 ion channel blockers rimantadine (Sun Pharma) and amantadine (Endo); (iii) favipiravir (Toyama Chemical), which inhibits the ribonucleic acid (RNA)-dependent RNA polymerase; and (iv) a cap-dependent endonuclease inhibitor, baloxariv marboxil (Shionogi) [<xref rid="B2-molecules-24-02603" ref-type="bibr">2</xref>,<xref rid="B3-molecules-24-02603" ref-type="bibr">3</xref>,<xref rid="B4-molecules-24-02603" ref-type="bibr">4</xref>]. M2 ion channel blockers have been previously used to treat influenza. However, the virus resistance of this class of medicine has been frequently reported to limit treatment efficiency.</p><p>The influenza A virus is a negative-sense single-strand RNA virus with a lipid envelope. The viral genome is divided into eight segments that encode nine structural proteins and a variable number of nonstructural proteins depending on the virus strain and host species. Each segment is packaged in a complex together with an RNA-dependent RNA polymerase, composed of polymerase basic 1 (PB1), polymerase basic 2 (PB2) and polymerase acidic (PA) proteins, involved in viral RNA transcription and replication [<xref rid="B2-molecules-24-02603" ref-type="bibr">2</xref>].</p><p>Each viral polymerase is an attractive target for developing a new antiviral compound. The inhibitors should work against several subtypes of influenza A viruses and be tolerated by a drug-resistant mutant because it is highly conserved in all influenza subtypes and is essential to the viral life cycle. We have previously reported on a highly potent antihuman immunodeficiency virus (HIV) nucleoside derivative called 4&#x02032;-ethynyl-2-fluoro-2&#x02032;-deoxyadenosine (EFdA, <bold>1</bold>, <xref ref-type="fig" rid="molecules-24-02603-f001">Figure 1</xref>) [<xref rid="B5-molecules-24-02603" ref-type="bibr">5</xref>,<xref rid="B6-molecules-24-02603" ref-type="bibr">6</xref>,<xref rid="B7-molecules-24-02603" ref-type="bibr">7</xref>,<xref rid="B8-molecules-24-02603" ref-type="bibr">8</xref>,<xref rid="B9-molecules-24-02603" ref-type="bibr">9</xref>,<xref rid="B10-molecules-24-02603" ref-type="bibr">10</xref>,<xref rid="B11-molecules-24-02603" ref-type="bibr">11</xref>,<xref rid="B12-molecules-24-02603" ref-type="bibr">12</xref>,<xref rid="B13-molecules-24-02603" ref-type="bibr">13</xref>]. EFdA is an adenosine derivative armed with an ethynyl group at the 4&#x02032;-position, which prevents the extension of a nucleotide at 3&#x02032;-OH because of its steric hindrance by the 4&#x02032;-substituent, providing features of a viral DNA chain terminator and a reverse transcriptase inhibitor [<xref rid="B14-molecules-24-02603" ref-type="bibr">14</xref>,<xref rid="B15-molecules-24-02603" ref-type="bibr">15</xref>,<xref rid="B16-molecules-24-02603" ref-type="bibr">16</xref>,<xref rid="B17-molecules-24-02603" ref-type="bibr">17</xref>,<xref rid="B18-molecules-24-02603" ref-type="bibr">18</xref>]. EFdA is currently used in human clinical trials [<xref rid="B19-molecules-24-02603" ref-type="bibr">19</xref>,<xref rid="B20-molecules-24-02603" ref-type="bibr">20</xref>,<xref rid="B21-molecules-24-02603" ref-type="bibr">21</xref>,<xref rid="B22-molecules-24-02603" ref-type="bibr">22</xref>,<xref rid="B23-molecules-24-02603" ref-type="bibr">23</xref>,<xref rid="B24-molecules-24-02603" ref-type="bibr">24</xref>]. Herein, we hypothesize that EFdA derivatives may work as an anti-influenza inhibitor. We subsequently describe the discovery of a new 4&#x02032;-ethynyl-2&#x02032;-deoxyadenosine 5&#x02032;-monophosphate analog called EdAP (<bold>5</bold>) as a potent inhibitor of influenza A virus. Interestingly, this DNA-type nucleic acid analog inhibited the multiplication of influenza A virus, although influenza A virus is an RNA virus that does not generate DNA.</p></sec><sec sec-type="results" id="sec2-molecules-24-02603"><title>2. Results and Discussion</title><sec id="sec2dot1-molecules-24-02603"><title>2.1. Effect of Compounds <bold>1</bold>&#x02013;<bold>3</bold> on Anti-Influenza Activities</title><p>We intended to analyze the anti-influenza activity of 4&#x02032;-ethynyl adenosine derivatives, namely EFdA (<bold>1</bold>), 4&#x02032;-ethynyl-2&#x02032;-deoxyadenosine (EdA, <bold>2</bold>) [<xref rid="B13-molecules-24-02603" ref-type="bibr">13</xref>], and 4&#x02032;-ethynyl-2-fluoroadenosine (EA, <bold>3</bold>), based on our hypothesis that EFdA analogs may work against the influenza virus [<xref rid="B25-molecules-24-02603" ref-type="bibr">25</xref>]. The adenosine derivatives of compounds <bold>1</bold>&#x02013;<bold>3</bold> were evaluated for their in vitro anti-influenza activities against the H1N1 virus using MDCK-SIAT1 according to a procedure that has been previously described [<xref rid="B26-molecules-24-02603" ref-type="bibr">26</xref>]. The deoxynucleoside-type derivatives <bold>1</bold> and <bold>2</bold> displayed modest and weak activities, respectively, whereas the nucleoside-type derivative <bold>3</bold> did not show any activity (<xref rid="molecules-24-02603-t001" ref-type="table">Table 1</xref>). The cytotoxicity of compounds <bold>1</bold>&#x02013;<bold>3</bold> was also determined using a cell counting kit-8 (CCK8) assay, and the following table presents the results. No cytotoxicity was observed at the highest concentration tested by the CCK8 assay (1 mM).</p><p>Here, 5&#x02032;-OH should have been triphosphorylated when derivatives <bold>1</bold> and <bold>2</bold> worked as a chain terminator in cells. This phosphorylation process was stepwise. First, 5&#x02032;-OH was transformed by cellular phosphatase into generating 5&#x02032;-<italic>O</italic>-monophosphate. Next, 5&#x02032;-monophosthate was transformed into 5&#x02032;-diphosphate and then into 5&#x02032;-triphosphate. We assumed that the cellular phosphatase involved in the first step could slowly phosphorylate the 5&#x02032;-OH of the derivatives because 5&#x02032;-OH was sterically hindered by the 4&#x02032;-ethynyl group. However, a 5&#x02032;-<italic>O</italic>-monophosphate analog could be much more efficiently phosphorylated by cellular phosphatase to generate a 5&#x02032;-diphosphate analog. We designed compounds <bold>4</bold> and <bold>5</bold> based on these assumptions (<xref ref-type="fig" rid="molecules-24-02603-f002">Figure 2</xref>) [<xref rid="B27-molecules-24-02603" ref-type="bibr">27</xref>]. Compounds <bold>4</bold> and <bold>5</bold> equipped the cyclosaligenyl (cycloSal) group on phosphate ester, which increased the compound permeability [<xref rid="B28-molecules-24-02603" ref-type="bibr">28</xref>,<xref rid="B29-molecules-24-02603" ref-type="bibr">29</xref>,<xref rid="B30-molecules-24-02603" ref-type="bibr">30</xref>]. This phosphate ester should have been cleaved by esterase in cells as a prodrug. We synthesized a 4&#x02032;-ethynyl-2-fluoro-2&#x02032;-deoxyadenosine 5&#x02032;-monophosphate analog called EFdAP (<bold>4</bold>, <xref ref-type="fig" rid="molecules-24-02603-f002">Figure 2</xref>) (data not shown) and evaluated its anti-influenza activity. However, the activity (IC<sub>50</sub> = 57 &#x003bc;M) was not improved when compared to EFdA. Therefore, we decided to synthesize and evaluate the activity of EdAP (<bold>5</bold>).</p></sec><sec id="sec2dot2-molecules-24-02603"><title>2.2. Synthesis of EdAP (<bold>5</bold>)</title><p>The synthesis of derivative <bold>5</bold> was initiated from diol <bold>6</bold> [<xref rid="B31-molecules-24-02603" ref-type="bibr">31</xref>] (<xref ref-type="scheme" rid="molecules-24-02603-sch001">Scheme 1</xref>). The <italic>tert</italic>-butyldiphenylsilyl (TBDPS) protection of &#x003b2;-methylene alcohol in <bold>6</bold> generated alcohol <bold>7</bold> in a 67% yield. The (2,2,6,6-tetramethylpiperidin-1-yl)oxyl (TEMPO) oxidation of alcohol <bold>7</bold> and the subsequent treatment of the resulting aldehyde <bold>8</bold> with tetrabromomethane and triphenylphosphine generated dibromoolefine <bold>9</bold> in a 96% yield over two steps [<xref rid="B32-molecules-24-02603" ref-type="bibr">32</xref>]. Dibromoolefine <bold>9</bold> was treated with <italic>n</italic>-BuLi, followed by chlorotriethylsilane(TESCl), to provide chlorotriethylsilane (TES)-protected alkyne <bold>10</bold> in an 83% yield. The treatment of the resulting acetal <bold>10</bold> with AcOH generated hemiacetal <bold>11</bold>, which was acetylated with Ac<sub>2</sub>O to afford diacetate <bold>12</bold> as a diastereomeric mixture of the acetoxy group in an 84% yield. The one-pot Silyl&#x02013;Hilbert&#x02013;Johnson reaction between adenine and acetate <bold>12</bold> furnished the desired adenosine derivative <bold>13</bold> in a 73% yield [<xref rid="B33-molecules-24-02603" ref-type="bibr">33</xref>,<xref rid="B34-molecules-24-02603" ref-type="bibr">34</xref>]. After the deacetylation of <bold>13</bold>, the resulting alcohol <bold>14</bold> was converted to phenylthiocarbonate <bold>15</bold> in a 63% yield, which was treated with Bu<sub>3</sub>SnH and azobisisobutyronitrile (AIBN) to generate deoxy adenosine derivative <bold>16</bold> in an 86% yield [<xref rid="B35-molecules-24-02603" ref-type="bibr">35</xref>,<xref rid="B36-molecules-24-02603" ref-type="bibr">36</xref>]. The deprotection of the TBDPS group in <bold>16</bold> and the introduction of phosphate ester by chlorophosphite <bold>17</bold> and H<sub>2</sub>O<sub>2</sub> aq, followed by the deprotection of the <italic>p</italic>-Methoxybenzyl (PMB) group by cerium ammonium nitrate (CAN), afforded EdAP (<bold>5</bold>).</p></sec><sec id="sec2dot3-molecules-24-02603"><title>2.3. Anti-Influenza Activity of EdAP (<bold>5</bold>)</title><p>The in vitro anti-influenza activity of compound <bold>5</bold> was analyzed (<xref ref-type="fig" rid="molecules-24-02603-f003">Figure 3</xref>). Consequently, compound <bold>5</bold> significantly inhibited the growth of the influenza virus, with an IC<sub>50</sub> of 3.8 &#x003bc;M, whereas no cytotoxicity was observed at the highest concentration tested by the CCK8 assay (1 mM). The maximum inhibition level of <bold>5</bold> was around a 79% decrease of influenza virus-produced NPs. This level is comparable to that of oseltamivir. Considering the result that the anti-influenza activity of the parent compound <bold>2</bold> was weak, phosphate ester <bold>5</bold> presumably worked as a prodrug. The introduced phosphate ester could be cleaved in cells to generate phosphate monoester. EdA (<bold>2</bold>) was easily hydrolyzed by adenosine deaminase to generate the corresponding inactive inosine derivative [<xref rid="B6-molecules-24-02603" ref-type="bibr">6</xref>,<xref rid="B11-molecules-24-02603" ref-type="bibr">11</xref>,<xref rid="B37-molecules-24-02603" ref-type="bibr">37</xref>]. However, EdAP, which has the same scaffold as EdA, except in the case of cyclosaligenyl phosphate ester, exhibited anti-influenza activity. Thus, the cycloSal phosphate group could prevent the conversion of EdAP by adenosine deaminase, or other unknown mechanisms may exist.</p></sec></sec><sec id="sec3-molecules-24-02603"><title>3. Materials and Methods</title><sec id="sec3dot1-molecules-24-02603"><title>3.1. Chemistry</title><p>Unless otherwise indicated, all the reactions were performed in oven-dried glassware fitted with a 3-way glass stopcock under an argon atmosphere and stirred with Teflon-coated magnetic stir bars. All work-up and purification procedures were performed with reagent-grade solvents under an ambient atmosphere. CH<sub>2</sub>Cl<sub>2</sub> was distilled from P<sub>2</sub>O<sub>5</sub> immediately before use. Et<sub>2</sub>O and tetrahydrofuran (THF) were distilled from sodium/benzophenone immediately before use. Et<sub>3</sub>N and <italic>N</italic>,<italic>N</italic>-diisopropylethylamine (DIEPA) were distilled from CaH<sub>2</sub> and stored over KOH. CH<sub>3</sub>CN and toluene were distilled from CaH<sub>2</sub> and stored over molecular sieves 4A. Chemical regents were of commercial grade and were used without any purification unless otherwise noted. Flash chromatography was performed on a PSQ-100B (Fuji Silysia Co., Ltd., Aichi, Japan) unless otherwise noted. Analysis thin layer chromatography (TLC) was performed using commercial silica gel plates (TLC Silica Gel 60 F<sub>254</sub>, Merck Millipore, Massachusetts, United States). Infrared spectra (IR) were recorded on a Jasco FT/IR-410 spectrometer using NaCl (neat). High-resolution mass spectra (HRMS) were obtained from an Applied Biosystems mass spectrometer (APIQSTAR pulsar I) for electrospray ionization (ESI). Polyethylene glycol was used as the internal standard. HRMS data are reported as <italic>m</italic>/<italic>z</italic> (relative intensity), with an accurate mass reported for the molecular ion [M + Na]<sup>+</sup>. <sup>1</sup>H and <sup>13</sup>C-NMR spectra were recorded on a Bruker 600 MHz spectrometer (Avance DRX-600) with CDCl<sub>3</sub> or MeOD as a solvent. Tetramethylsilane (TMS) was used as an internal standard (&#x003b4; 0.0) for <sup>1</sup>H-NMR. Chemical shifts for <sup>13</sup>C-NMR were reported in ppm relative to the center line of a triplet at 77.0 ppm in CDCl<sub>3</sub> or a septet at 49.0 ppm in MeOD as a solvent. Multiplicities are indicated as br (broad), s (singlet), d (doublet), t (triplet), q (quartet), or m (multiplet). Coupling constants (<italic>J</italic>) are reported in hertz (Hz). The diastereomeric ratio was determined by <sup>1</sup>H-NMR analysis. Optical rotations were determined using a JASCO P-1010 digital polarimeter in 100-mm cells and with a sodium D line (589 nm) at room temperature in the solvent and concentration indicated.</p><sec id="sec3dot1dot1-molecules-24-02603"><title>3.1.1. Synthesis of ((3a<italic>R</italic>,5<italic>R</italic>,6<italic>S</italic>,6a<italic>R</italic>)-5-(((<italic>tert</italic>-butyldiphenylsilyl)oxy)methyl)-6-((4-methoxybenzyl)oxy)-2,2-dimethyltetrahydrofuro [2,3-<italic>d</italic>][1,3]dioxol-5-yl)methanol (<bold>7</bold>)</title><p>To a stirred solution of diol <bold>6</bold> (10.3 g, 30 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (40 mL) and Et<sub>3</sub>N (20 mL) was added <italic>tert</italic>-butylchlorodiphenylsilane (7.1 mL, 27 mmol). After stirring for 16 h, saturated aqueous NaCO<sub>3</sub> solution was added to the mixture. The resulting reaction mixture was extracted with EtOAc, and the combined organic layer was washed with H<sub>2</sub>O, dried over brine and Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to afford alcohol <bold>7</bold> (10.9 g, 63%) as a white crystal. <bold>7</bold>: Colorless crystal; <italic>R</italic><sub>f</sub> 0.8 (hexane/EtOAc = 1/1); [&#x003b1;]<sub>D</sub><sup>20</sup> + 38.1 (<italic>c</italic> 1.15, CHCl<sub>3</sub>); <sup>1</sup>H-NMR (600 MHz, CDCl<sub>3</sub>), <italic>&#x003b4;</italic> in ppm 7.63&#x02013;7.59 (m, 4H), 7.44&#x02013;7.40 (m, 2H), 7.38&#x02013;7.35 (m, 4H), 7.28 (d, <italic>J</italic> = 8.6 Hz, 2H), 6.86 (d, <italic>J</italic> = 8.6 Hz, 2H), 5.81 (d, <italic>J</italic> = 3.8 Hz, 1H), 4.75 (d, <italic>J</italic> = 11.6 Hz, 1H), 4.67 (dd, <italic>J</italic> = 5.2, 3.8 Hz, 1H), 4.45 (d, <italic>J</italic> = 11.6 Hz, 1H), 4.42 (d, <italic>J</italic> = 5.2 Hz, 1H), 3.81 (dd, <italic>J</italic> = 11.9, 6.4 Hz, 1H), 3.79 (dd, <italic>J</italic> = 11.9, 7.2 Hz, 1H), 3.79 (s, 3H), 3.75 (d, <italic>J</italic> = 11.1 Hz, 1H), 3.66 (d, <italic>J</italic> = 11.1 Hz, 1H), 2.41 (dd, <italic>J</italic> = 7.2, 6.4 Hz, 1H), 1.65 (s, 3H), 1.37 (s, 3H), 0.99 (s, 9H); <sup>13</sup>C-NMR (150 MHz, CDCl<sub>3</sub>) &#x003b4;<sub>C</sub> 159.5, 135.60 (2C), 135.55 (2C), 133.2, 133.0, 129.74, 129.67, 129.5 (2C), 129.3, 127.71 (2C), 127.68 (2C), 114.0 (2C), 113.7, 104.5, 87.4, 79.2, 77.5, 72.2, 65.4, 63.3, 55.2, 26.9, 26.8 (3C), 26.3, 19.2; IR &#x003bd;<sub>max</sub> (film) 3545, 2939, 2862, 1612, 1514, 1464, 1429, 1379, 1250, 1215, 1107, 1028 cm<sup>&#x02212;1</sup>; HRMS (ESI) <italic>m</italic>/<italic>z</italic> = calcd 601.2592 [M + Na]<sup>+</sup>, found 601.2600 [M + Na]<sup>+</sup>; mp 113 &#x000b0;C (see <xref ref-type="app" rid="app1-molecules-24-02603">Supplementary Materials</xref>).</p></sec><sec id="sec3dot1dot2-molecules-24-02603"><title>3.1.2. Synthesis of tert-butyl(((3aR,5R,6S,6aR)-5-(2,2-dibromovinyl)-6-((4-methoxybenzyl)oxy)-2,2- dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)methoxy)diphenylsilane (<bold>9</bold>)</title><p>To a stirred solution of <bold>7</bold> (17.4 g, 30 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (60 mL) and NaHCO<sub>3</sub> (60 mL, 0.25 M in H<sub>2</sub>O) were added TEMPO (47 mg, 0.3 mmol) and KBr (360 mg, 3.0 mmol). After the slow addition of NaOCl (24 mL, 12% in H<sub>2</sub>O) at 0 &#x000b0;C, the resulting mixture was stirred for 30 min. The resulting reaction mixture was extracted with EtOAc, and the combined organic layer was washed with H<sub>2</sub>O, dried over brine and Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure to give crude aldehyde <bold>8</bold>, which was directly used in the next step without further purification. To a stirred solution of the above aldehyde <bold>8</bold> in CH<sub>2</sub>Cl<sub>2</sub> (100 mL) and Et<sub>3</sub>N (16.7 mL, 120 mmol) were added CBr<sub>4</sub> (20 g, 60 mmol) and PPh<sub>3</sub> (31.5 g, 120 mmol) at 0 &#x000b0;C. After stirring for 18 h at room temperature (rt), the reaction was quenched with H<sub>2</sub>O. After filtration of the resulting reaction mixture through a pad of celite, the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to afford dibromoolefine <bold>9</bold> (21 g, 96%) as a colorless oil. <bold>9</bold>: Pale yellow oil; <italic>R</italic><sub>f</sub> 0.6 (hexane/EtOAc = 4/1); [&#x003b1;]<sub>D</sub><sup>19</sup> &#x02212;40.1 (<italic>c</italic> 1.02, CHCl<sub>3</sub>); <sup>1</sup>H-NMR (600 MHz, CDCl<sub>3</sub>), &#x003b4; in ppm 7.66&#x02013;7.61 (m, 4H), 7.44&#x02013;7.30 (m, 8H), 7.08 (s, 1H), 6.86 (d, <italic>J</italic> = 8.6 Hz, 2H), 5.73 (d, <italic>J</italic> = 4.0 Hz, 1H), 4.75 (d, <italic>J</italic> = 11.9 Hz, 1H), 4.62 (d, <italic>J</italic> = 11.9 Hz, 1H), 4.55 (dd, <italic>J</italic> = 4.3, 4.0, 1H), 4.35 (d, <italic>J</italic> = 4.3 Hz, 1H), 3.99 (d, <italic>J</italic> = 11.6 Hz, 1H), 3.77 (s, 3H), 3.54 (d, <italic>J</italic> = 11.6, 1H), 1.58 (s, 3H), 1.32 (s, 3H), 0.98 (s, 9H); <sup>13</sup>C-NMR (150 MHz, CDCl<sub>3</sub>) &#x003b4;<sub>C</sub> 170.9, 159.5, 135.9 (2C), 135.5 (2C), 135.3, 133.5, 132.6, 129.7 (2C), 129.6 (2C), 129.4, 127.7 (2C), 127.6 (2C), 114.0 (2C), 113.1, 103.8, 90.5, 85.6, 76.1, 72.2, 61.6, 55.2, 26.8 (3C), 26.0, 25.8, 19.3; IR &#x003bd;<sub>max</sub> (film) 3047, 2862, 1608, 1514, 1252, 1107, 1024 cm<sup>&#x02212;1</sup>; HRMS (ESI) <italic>m</italic>/<italic>z</italic> = calcd 753.0853 [M + Na]<sup>+</sup>, found 753.0877 [M + Na]<sup>+</sup>.</p></sec><sec id="sec3dot1dot3-molecules-24-02603"><title>3.1.3. Synthesis of tert-butyl(((3aR,5R,6S,6aR)-6-((4-methoxybenzyl)oxy)-2,2-dimethyl-5-((triethylsilyl) ethynyl)tetrahydrofuro[2,3-d][1,3]dioxol-5-yl)methoxy)diphenylsilane (<bold>10</bold>)</title><p>To a stirred solution of dibromoalkene <bold>9</bold> (21 g, 29 mmol) in THF (300 mL) was added <italic>n</italic>-BuLi (20.9 mL, 2.76 M in hexane) at &#x02212;78 &#x000b0;C. After stirring for 2 h at &#x02212;30 &#x000b0;C, <italic>n</italic>-BuLi (4.2 mL, 2.76 M in hexane) was added. After stirring for 1 h at &#x02212;30 &#x000b0;C, chlorotriethylsilane (5 mL, 30 mmol) was added at &#x02212;78 &#x000b0;C. After stirring for 2 h at &#x02212;78 &#x000b0;C, the reaction was quenched with H<sub>2</sub>O at 0 &#x000b0;C. The resulting mixture was extracted with EtOAc, and the combined organic layer was washed with H<sub>2</sub>O, dried over brine and Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to afford acetonide <bold>10</bold> (16.5 g, 83%) as a colorless oil. <bold>10</bold>: Pale yellow oil; <italic>R</italic><sub>f</sub> 0.7 (hexane/EtOAc = 4/1); [&#x003b1;]<sub>D</sub><sup>22</sup> -49.0 (<italic>c</italic> 0.52, CHCl<sub>3</sub>); <sup>1</sup>H-NMR (600 MHz, CDCl<sub>3</sub>), &#x003b4; in ppm 7.63&#x02013;7.60 (m, 4H), 7.44&#x02013;7.35 (m, 6H), 7.31 (d, <italic>J</italic> = 8.6 Hz, 2H), 6.83 (d, <italic>J</italic> = 8.6 Hz, 2H), 5.73 (d, <italic>J</italic> = 3.5 Hz, 1H), 4.70&#x02013;4.64 (m, 3H), 4.41 (d, <italic>J</italic> = 4.7 Hz, 1H), 3.91 (d, <italic>J</italic> = 11.3 Hz, 1H), 3.78 (s, 3H), 3.70 (d, <italic>J</italic> = 11.3 Hz, 1H), 1.74 (s, 3H), 1.36 (s, 3H), 0.97 (s, 9H), 0.93 (t, <italic>J</italic> = 7.9 Hz, 9H), 0.56 (q, <italic>J</italic> = 7.9 Hz, 6H); <sup>13</sup>C-NMR (150 MHz, CDCl<sub>3</sub>) &#x003b4;<sub>C</sub> 159.2, 135.7 (2C), 135.5 (2C), 133.3, 132.7, 130.0, 129.73, 129.69, 129.2 (2C), 127.71 (2C), 127.70 (2C), 114.1, 113.7 (2C), 103.9, 103.4, 90.9, 81.9, 79.5, 76.4, 71.9, 67.3, 55.2, 26.8 (3C), 26.5, 26.4, 19.3, 7.4 (3C), 4.1 (3C); IR &#x003bd;<sub>max</sub> (film) 2952, 2166, 1514, 1462, 1167 cm<sup>-1</sup>; HRMS (ESI) <italic>m</italic>/<italic>z</italic> = calcd 709.3351 [M + Na]<sup>+</sup>, found 709.3358 [M + Na]<sup>+</sup>.</p></sec><sec id="sec3dot1dot4-molecules-24-02603"><title>3.1.4. Synthesis of (3R,4S,5R)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-4-((4-methoxybenzyl)oxy)-5- ((triethylsilyl)ethynyl)tetrahydrofuran-2,3-diyl diacetate (<bold>12</bold>)</title><p>A solution of acetonide <bold>10</bold> (16.5 g, 24 mmol) in AcOH (240 mL) and H<sub>2</sub>O (60 mL) was stirred for 5 h at 65 &#x000b0;C. Concentration of the reaction mixture with toluene gave crude hemiacetal <bold>11</bold>, which was directly used in the next step without further purification. A solution of the above crude hemiacetal <bold>11</bold> in pyridine (60 mL) and Ac<sub>2</sub>O (20 mL) was stirred for 10 h at rt. After concentration of the reaction mixture with toluene, the resulting residue was purified by silica gel column chromatography to afford acetal <bold>12</bold> (14.5 g, 83%) as a colorless oil. <bold>12</bold>: Pale yellow oil; <italic>R</italic><sub>f</sub> 0.5 (hexane/EtOAc = 4/1); <sup>1</sup>H-NMR (600 MHz, CHCl<sub>3</sub>), &#x003b4; in ppm 7.67&#x02013;7.62 (m, 4H), 7.44&#x02013;7.40 (m, 2H), 7.38&#x02013;7.35 (m, 4H), 7.24 (d, <italic>J</italic> = 8.6 Hz, 2H), 6.84 (d, <italic>J</italic> = 8.6 Hz, 2H), 6.28 (s, 1H), 5.36 (d, <italic>J</italic> = 4.9 Hz, 1H), 4.60&#x02013;4.55 (3H, overlapped), 3.85 (d, <italic>J</italic> = 11.1 Hz, 1H), 3.79 (s, 3H), 3.77 (d, <italic>J</italic> = 11.1 Hz, 1H), 2.09 (s, 3H), 1.80 (s, 3H), 1.05 (s, 9H), 0.92 (t, <italic>J</italic> = 7.9 Hz, 9H), 0.55 (q, <italic>J</italic> = 7.9 Hz, 6H); HRMS (ESI) <italic>m</italic>/<italic>z</italic> = calcd 753.3249 [M + Na]<sup>+</sup>, found 753.3259 [M + Na]<sup>+</sup>.</p></sec><sec id="sec3dot1dot5-molecules-24-02603"><title>3.1.5. Synthesis of (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-4- ((4-methoxybenzyl)oxy)-5-((triethylsilyl)ethynyl)tetrahydrofuran-3-yl acetate (<bold>13</bold>)</title><p>To a stirred solution of acetal <bold>12</bold> (5.7 g, 7.8 mmol) in 1,2-dichloroethane (15 mL) were added adenine (3.2 g, 24 mmol) and <italic>N</italic>,<italic>O</italic>-bis(trimethylsilyl)acetamide (11.5 mL, 47 mmol). After stirring for 5 h under reflux conditions, trimethylsilyl trifluoromethanesulfonate (TMSOTf) (4.2 mL, 23 mmol) was added at 0 &#x000b0;C. After stirring for 10 h under reflux conditions, a saturated NaHCO<sub>3</sub> solution was added to the mixture at rt. After filtration of the resulting mixture through a pad of celite, the filtrate was extracted with EtOAc, and the combined organic layer was washed with H<sub>2</sub>O, dried over brine and Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to afford nucleoside <bold>13</bold> (4.6 g, 73%) as a colorless oil. <bold>13</bold>: Colorless oil; <italic>R</italic><sub>f</sub> 0.3 (Hexane/EtOAc = 1/2); [&#x003b1;]<sub>D</sub><sup>20</sup> -31.3 (<italic>c</italic> 0.61, CHCl<sub>3</sub>); <sup>1</sup>H-NMR (600 MHz, CDCl<sub>3</sub>), &#x003b4; in ppm 8.19 (s, 1H), 7.91 (s, 1H), 7.65&#x02013;7.62 (m, 4H), 7.45&#x02013;7.36 (m, 2H), 7.34&#x02013;7.32 (m, 4H), 7.27 (d, <italic>J</italic> = 8.5 Hz, 2H), 6.85 (d, <italic>J</italic> = 8.5 Hz, 2H), 6.28 (d, <italic>J</italic> = 5.0 Hz, 1H), 5.93 (1H, dd, <italic>J</italic> = 6.1, 5.0 Hz, 1H), 5.47 (brs, 2H), 4.82 (d, <italic>J</italic> = 6.1 Hz, 1H), 4.73 (d, <italic>J</italic> = 11.1 Hz, 1H), 4.54 (d, <italic>J</italic> = 11.1 Hz, 1H), 4.03 (d, <italic>J</italic> = 11.2 Hz, 1H), 3.81 (d, <italic>J</italic> = 11.2 Hz, 1H), 3.80 (s, 3H), 2.02 (s, 3H), 1.03 (s, 9H), 0.96 (t, <italic>J</italic> = 7.9 Hz, 9H), 0.59 (q, <italic>J</italic> = 7.9 Hz, 6H); <sup>13</sup>C-NMR (150 MHz, CDCl<sub>3</sub>) &#x003b4;<sub>C</sub> 170.0, 159.2, 155.3, 153.2, 149.8, 139.7, 135.6 (2C), 135.5 (2C), 132.64, 132.56, 129.89, 129.86, 129.82, 129.3 (2C), 127.7 (4C), 120.1, 113.6 (2C), 102.0, 91.6, 86.5, 83.5, 76.5, 73.6, 73.3, 66.7, 55.3, 26.8 (3C), 20.6, 19.2, 7.4 (3C), 4.2 (3C); IR &#x003bd;<sub>max</sub> (film) 3319, 3167, 2170, 1745, 1599, 1469 cm<sup>&#x02212;1</sup>; HRMS (ESI) <italic>m</italic>/<italic>z</italic> = calcd 828.3583 [M + Na]<sup>+</sup>, found 828.3559 [M + Na]<sup>+</sup>.</p></sec><sec id="sec3dot1dot6-molecules-24-02603"><title>3.1.6. Synthesis of (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-4-((4- methoxybenzyl)oxy)-5-((triethylsilyl)ethynyl)tetrahydrofuran-3-ol (<bold>14</bold>)</title><p>A solution of nucleoside <bold>13</bold> (4.6 g, 5.7 mmol) in MeOH (60 mL) and Et<sub>3</sub>N (15 mL) was stirred for 18 h at rt. After concentration of the reaction mixture, the resulting residue was purified by silica gel column chromatography to afford alcohol <bold>14</bold> (3.5 g, 80%) as a colorless oil. <bold>14</bold>: Colorless oil; <italic>R</italic><sub>f</sub> 0.5 (EtOAc); [&#x003b1;]<sub>D</sub><sup>21</sup> &#x02212;19.8 (<italic>c</italic> 0.66, CDCl<sub>3</sub>); <sup>1</sup>H-NMR (600 MHz, CHCl<sub>3</sub>), &#x003b4; in ppm 8.20 (s, 1H), 7.90 (s, 1H), 7.62&#x02013;7.60 (m, 4H), 7.43&#x02013;7.40 (m, 2H), 7.34&#x02013;7.32 (m, 6H), 6.88 (d, <italic>J</italic> = 8.6 Hz, 2H), 6.07 (d, <italic>J</italic> = 5.1 Hz, 1H), 5.48 (br s, 2H), 4.91 (d, <italic>J</italic> = 11.2 Hz, 1H), 4.87 (ddd, <italic>J</italic> = 7.9, 6.1, 5.1 Hz, 1H), 4.67 (d, <italic>J</italic> = 11.2 Hz, 1H), 4.58 (d, <italic>J</italic> = 6.1 Hz, 1H), 3.99 (d, <italic>J</italic> = 11.0 Hz, 1H), 3.83 (d, <italic>J</italic> = 11.0 Hz, 1H), 3.81 (s, 3H), 3.56 (d, <italic>J</italic> = 7.9 Hz, 1H), 1.02 (s, 9H), 0.97 (t, <italic>J</italic> = 7.9 Hz, 9H), 0.62 (q, <italic>J</italic> = 7.9 Hz, 6H); <sup>13</sup>C-NMR (150 MHz, CDCl3) &#x003b4;<sub>C</sub> 159.6, 155.3, 153.0, 149.7, 139.8, 135.6 (2C), 135.5 (2C), 132.6, 132.5, 129.92, 129.89, 129.7 (2C), 129.2, 127.78 (2C), 127.76 (2C), 120.2, 113.9 (2C), 102.5, 92.1, 89.9, 83.3, 77.3, 73.2, 73.0, 66.9, 55.3, 26.8 (3C), 19.2, 7.4 (3C), 4.2 (3C); IR &#x003bd;<sub>max</sub> (film) 3327, 3172, 2170, 1645, 1471, 1109 cm<sup>&#x02212;1</sup>; HRMS (ESI) <italic>m</italic>/<italic>z</italic> = calcd 786.3482 [M + Na]<sup>+</sup>, found 786.3499 [M + Na]<sup>+</sup>.</p></sec><sec id="sec3dot1dot7-molecules-24-02603"><title>3.1.7. Synthesis of <italic>O</italic>-((2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-4- ((4-methoxybenzyl)oxy)-5-((triethylsilyl)ethynyl)tetrahydrofuran-3-yl) <italic>O</italic>-phenyl carbonothioate (<bold>15</bold>)</title><p>To a stirred solution of alcohol <bold>14</bold> (3.5 g, 4.6 mmol) in MeCN (30 mL) were added <italic>N</italic>,<italic>N</italic>-dimethyl-4-aminopyridine (DMAP) (1.1 g, 9.2 mmol) and <italic>O</italic>-phenyl carbonochloridothioate (635 &#x003bc;L, 4.6 mmol) at 0 &#x000b0;C. After stirring for 21 h, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to afford thiocarbonate <bold>15</bold> (2.6 g, 63%) as a colorless oil. <bold>15</bold>: Colorless oil; <italic>R</italic><sub>f</sub> 0.6 (hexane/EtOAc = 1/2); [&#x003b1;]<sub>D</sub><sup>21</sup> &#x02212;63.8 (<italic>c</italic> 0.52, CHCl<sub>3</sub>); <sup>1</sup>H-NMR (600 MHz, CDCl<sub>3</sub>), &#x003b4; in ppm 8.15 (s, 1H), 7.91 (s, 1H), 7.67&#x02013;7.63 (m, 4H), 7.43-7.39 (m, 2H), 7.37&#x02013;7.28 (m, 9H), 6.91 (d, <italic>J</italic> = 8.3 Hz, 2H), 6.87 (d, <italic>J</italic> = 8.7 Hz, 2H), 6.47 (dd, <italic>J</italic> = 5.9, 5.3 Hz, 1H), 6.41 (d, <italic>J</italic> = 5.3 Hz, 1H), 5.49 (brs, 2H), 5.11 (d, <italic>J</italic> = 5.9 Hz, 1H), 4.87 (d, <italic>J</italic> = 11.0 Hz, 1H), 4.64 (d, <italic>J</italic> = 11.0 Hz, 1H), 4.11 (d, <italic>J</italic> = 11.2 Hz, 1H), 3.86 (d, <italic>J</italic> = 11.2 Hz, 1H), 3.81 (s, 3H), 1.03 (s, 9H), 0.97 (t, <italic>J</italic> = 7.9 Hz, 9H), 0.61 (q, <italic>J</italic> = 7.9 Hz, 6H); <sup>13</sup>C-NMR (150 MHz, CDCl<sub>3</sub>) &#x003b4;<sub>C</sub> 194.3, 159.3, 155.3, 153.4, 153.3, 149.9, 140.1, 135.64 (2C), 135.61 (2C), 132.6 (2C), 129.9, 129.81, 129.80, 129.6 (2C), 129.5 (2C), 127.75 (2C), 127.73 (2C), 126.6, 121.7 (2C), 120.2, 113.7 (2C), 101.8, 92.2, 86.2, 83.6, 80.6, 76.2, 73.8, 66.6, 55.3, 26.8 (3C), 19.2, 7.4 (3C), 4.2 (3C); IR &#x003bd;<sub>max</sub> (film) 3315, 2956, 2171, 1643, 1105, 1009 cm<sup>&#x02212;1</sup>; HRMS (ESI) <italic>m</italic>/<italic>z</italic> = calcd 922.3460 [M + Na]<sup>+</sup>, found 922.3451 [M + Na]<sup>+</sup>.</p></sec><sec id="sec3dot1dot8-molecules-24-02603"><title>3.1.8. Synthesis of 9-((2R,4S,5R)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-4-((4-methoxybenzyl)oxy)-5-((triethylsilyl)ethynyl)tetrahydrofuran-2-yl)-9H-purin-6-amine (<bold>17</bold>)</title><p>To a stirred solution of thiocarbonate <bold>15</bold> (2.6 g, 2.9 mmol) in toluene (60 mL) were added HSnBu<sub>3</sub> (4.6 mL, 17 mmol) and AIBN (117 mg, 0.7 mmol). After stirring for 30 min at 130 &#x000b0;C, the reaction mixture was concentrated under reduced pressure. The resulting residue was roughly purified by silica gel column chromatography to afford nucleoside <bold>16</bold> as a colorless oil. To a stirred solution of nucleoside <bold>16</bold> above in THF (20 mL) was added tetra-<italic>n</italic>-butylammonium fluoride (TBAF) (4.8 mL, 1 M in THF) at rt. After stirring for 2 h, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to afford alcohol <bold>17</bold> (982 mg, 86%) as a colorless oil. <bold>17</bold>: Pale yellow crystal; <italic>R</italic><sub>f</sub> 0.5 (EtOAc); [&#x003b1;]<sub>D</sub><sup>21</sup> + 6.41 (<italic>c</italic> 0.56, CHCl<sub>3</sub>); <sup>1</sup>H-NMR (600 MHz, CDCl<sub>3</sub>), &#x003b4; in ppm 8.30 (s, 1H), 7.77 (s, 1H), 7.35 (d, <italic>J</italic> = 8.4 Hz, 2H), 6.90 (d, <italic>J</italic> = 8.4 Hz, 2H), 6.80 (br d, <italic>J</italic> = 12.3 Hz, 1H), 6.36 (dd, <italic>J</italic> = 9.2, 5.7 Hz, 1H), 5.76 (brs, 2H), 4.82 (d, <italic>J</italic> = 11.3 Hz, 1H), 4.60 (d, <italic>J</italic> = 11.3 Hz, 1H), 4.52 (d, <italic>J</italic> = 5.8 Hz, 1H), 4.06 (d, <italic>J</italic> = 12.5 Hz, 1H), 3.84 (dd, <italic>J</italic> = 12.5, 12.3 Hz, 1H), 3.82 (s, 3H), 3.09 (ddd, <italic>J</italic> = 13.5, 9.2, 5.8 Hz, 1H), 2.72 (s, 1H), 2.44 (dd, <italic>J</italic> = 13.5, 5.7 Hz, 1H); <sup>13</sup>C-NMR (150 MHz, CDCl<sub>3</sub>) &#x003b4;<sub>C</sub> 159.4, 155.9, 152.4, 148.5, 140.2, 129.6, 129.4 (2C), 121.2, 113.9 (2C), 87.2, 86.7, 80.3, 79.7, 77.0, 72.5, 68.6, 55.3, 38.8; IR &#x003bd;<sub>max</sub> (film) 3298, 2949, 2400, 1682, 1514, 1425 cm<sup>&#x02212;1</sup>; HRMS (ESI) <italic>m</italic>/<italic>z</italic> = calcd 418.1485 [M + Na]<sup>+</sup>, found 418.1488 [M + Na]<sup>+</sup>.</p></sec><sec id="sec3dot1dot9-molecules-24-02603"><title>3.1.9. Synthesis of 2-(((2R,3S,5R)-5-(6-amino-9H-purin-9-yl)-2-ethynyl-3-((4-methoxybenzyl)oxy) tetrahydrofuran-2-yl)methoxy)-4H-benzo[d][1,3,2]dioxaphosphinine 2-oxide (<bold>18</bold>)</title><p>To a stirred solution of alcohol <bold>17</bold> (200 mg, 0.51 mmol) in MeCN (5 mL) were added DIPEA (178 &#x003bc;L, 1.0 mmol) and 2-chloro-4<italic>H</italic>-benzo[d][1,3,2]dioxaphosphinine (192 mg, 0.51 mmol) at 0 &#x000b0;C. After stirring for 1 h at 0 &#x000b0;C, H<sub>2</sub>O<sub>2</sub> (250 &#x003bc;L, 30% in H<sub>2</sub>O) was added at 0 &#x000b0;C. After stirring for 1 h at 0 &#x000b0;C, the resulting mixture was directly purified by silica gel column chromatography to afford phosphoester <bold>18</bold> (220 mg, 76%) as a colorless oil. <bold>18</bold>: Pale yellow oil; <italic>R</italic><sub>f</sub> 0.7 (CHCl<sub>3</sub>/MeOH = 8/1); [&#x003b1;]<sub>D</sub><sup>21</sup> &#x02212;7.85 (<italic>c</italic> 0.53, CHCl3); <sup>1</sup>H-NMR (600 MHz, CDCl<sub>3</sub>), &#x003b4; in ppm major-isomer 8.19 (s, 1H), 7.78 (s, 1H), 7.32&#x02013;7.24 (4H, overlapped), 7.12&#x02013;7.09 (m, 1H), 6.99&#x02013;6.94 (2H, overlapped), 6.90&#x02013;6.86 (2H, overlapped), 6.34&#x02013;6.31 (1H, overlapped), 5.60 (2H, brs), 5.26&#x02013;5.14 (2H, overlapped), 4.72&#x02013;4.67 (2H, overlapped), 4.58 (d, <italic>J</italic> = 11.6 Hz, 1H), 4.52&#x02013;4.49 (m, 1H), 4.37&#x02013;4.34 (m, 1H), 3.80 (s, 3H), 2.89&#x02013;2.85 (1H, overlapped), 2.67 (s, 1H), 2.66&#x02013;2.61 (1H, overlapped); minor-isomer 8.26 (s, 1H), 7.80 (s, 1H), 7.32&#x02013;7.24 (4H, overlapped), 7.09&#x02013;7.06 (m, 1H), 6.99&#x02013;6.94 (2H, overlapped), 6.90&#x02013;6.86 (2H, overlapped), 6.34&#x02013;6.31 (1H, overlapped), 5.62 (2H, brs), 5.26&#x02013;5.14 (2H, overlapped), 4.72&#x02013;4.67 (2H, overlapped), 4.62 (d, <italic>J</italic> = 11.6 Hz, 1H), 4.47&#x02013;4.44 (m, 1H), 4.41&#x02013;4.38 (m, 1H), 3.81 (s, 3H), 2.89&#x02013;2.85 (1H, overlapped), 2.67 (s, 1H), 2.66&#x02013;2.61 (1H, overlapped); IR &#x003bd;<sub>max</sub> (film) 3175, 2114, 1643, 1597, 1513, 1458 cm<sup>&#x02212;1</sup>; HRMS (ESI) <italic>m</italic>/<italic>z</italic> = calcd 586.1462 [M + Na]<sup>+</sup>, found 586.1467 [M + Na]<sup>+</sup>.</p></sec><sec id="sec3dot1dot10-molecules-24-02603"><title>3.1.10. Synthesis of 2-(((2R,3S,5R)-5-(6-amino-9H-purin-9-yl)-2-ethynyl-3-hydroxytetrahydrofuran-2-yl) methoxy)-4H-benzo[d][1,3,2]dioxaphosphinine 2-oxide (<bold>5</bold>)</title><p>To a stirred solution of phosphoester <bold>18</bold> (156 mg, 0.28 mmol) in MeCN (2.5 mL) and H<sub>2</sub>O (0.5 mL) was added ceric ammonium nitrate (614 mg, 1.1 mmol) at 0 &#x000b0;C. After stirring for 20 min at 0 &#x000b0;C, the resulting mixture was directly purified by silica gel column chromatography to afford <bold>5</bold> (93 mg, 75%) as a white solid. <bold>5</bold>: Colorless crystal; <italic>R</italic><sub>f</sub> 0.5 (EtOAc/MeOH = 10/1); <sup>1</sup>H-NMR (600 MHz, MeOD), &#x003b4; in ppm major-isomer 8.34 (s, 1H), 8.26 (s, 1H), 7.30&#x02013;7.26 (1H, overlapped), 7.15&#x02013;7.11 (1H, overlapped), 7.07&#x02013;7.06 (m, 1H), 6.96&#x02013;6.94 (m, 1H), 6.45&#x02013;6.41 (1H, overlapped), 5.43&#x02013;5.26 (2H, overlapped), 4.94&#x02013;4.87 (1H, overlapped), 4.44&#x02013;4.35 (2H, overlapped), 3.21 (s, 1H), 2.94&#x02013;2.89 (1H, overlapped), 2.73&#x02013;2.67 (1H, overlapped); minor-isomer 8.37 (s, 1H), 8.30 (s, 1H), 7.30&#x02013;7.26 (1H, overlapped), 7.15&#x02013;7.11 (2H, overlapped), 6.91 (d, <italic>J</italic> = 8.2 Hz, 1H), 6.45-6.41 (1H, overlapped), 5.43&#x02013;5.26 (2H, overlapped), 4.94&#x02013;4.87 (1H, overlapped), 4.44&#x02013;4.35 (2H, overlapped), 3.19 (s, 1H), 2.94&#x02013;2.89 (1H, overlapped), 2.73-2.67 (1H, overlapped); <sup>13</sup>C-NMR (150 MHz, MeOD) &#x003b4;<sub>C</sub> major-isomer 152.2, 151.0 (d, <italic>J</italic><sub>C-P</sub> = 6.5 Hz), 149.4, 145.9, 144.2, 131.0, 126.7, 125.81, 122.0, 120.7, 119.3 (d, <italic>J</italic><sub>C-P</sub> = 8.8 Hz), 84.8, 84.41, 80.12, 78.7, 71.5, 70.0 (d, <italic>J</italic><sub>C-P</sub> = 6.6 Hz), 38.42; Minor-isomer 152.3, 150.9 (d, <italic>J</italic><sub>C-P</sub> = 7.6 Hz), 149.5, 146.0, 144.1, 130.9, 126.8, 125.79, 121.9, 120.6, 119.2 (d, <italic>J</italic><sub>C-P</sub> = 7.7 Hz), 84.7, 84.36, 80.06, 78.8, 71.6, 70.2 (d, <italic>J</italic><sub>C-P</sub> = 6.5 Hz), 38.37; IR &#x003bd;<sub>max</sub> (film) 3246, 3070, 2115, 1688, 1609, 1489 cm<sup>&#x02212;1</sup>; UV (MeOH) &#x003bb;<sub>max</sub> (log &#x003b5;) 212 (4.35), 261 (3.83) nm; HRMS (ESI) <italic>m</italic>/<italic>z</italic> = calcd 466.0886 [M + Na]<sup>+</sup>, found 466.0889 [M + Na]<sup>+</sup>.</p></sec></sec><sec id="sec3dot2-molecules-24-02603"><title>3.2. Biological Assays</title><sec id="sec3dot2dot1-molecules-24-02603"><title>3.2.1. Cells</title><p>MDCK cells and MDCK&#x02013;SIAT1 cells were cultivated in minimal essential medium (MEM), which was supplemented with 10% heat-inactivated fetal bovine serum from Tissue Culture Biological, Tulare, CA, and 1% penicillin-streptomycin solution from GIBCO-BRL, Rockville, MD.</p></sec><sec id="sec3dot2dot2-molecules-24-02603"><title>3.2.2. Virus</title><p>As described previously [<xref rid="B38-molecules-24-02603" ref-type="bibr">38</xref>], the number of influenza A/Narita/1/09 H1N1pdm viruses were increased in MDCK&#x02013;SIAT1 cells containing 1% penicillin-streptomycin solution and 5 &#x003bc;g/mL acetylated trypsin at 37 &#x000b0;C in 5% CO<sub>2</sub> atmosphere for 3 days. The viruses in the culture were harvested, pooled, and clarified before concentration and resuspension in cold phosphate-buffered saline. After aliquoting, aliquots were kept at &#x02212;80 &#x000b0;C until use.</p></sec><sec id="sec3dot2dot3-molecules-24-02603"><title>3.2.3. Cytotoxicity Assay</title><p>As described previously [<xref rid="B39-molecules-24-02603" ref-type="bibr">39</xref>], each inhibitor was serially diluted in serum-free MEM and transferred onto confluent monolayers of MDCK&#x02013;SIAT1. After incubation at 37 &#x000b0;C in a 5% CO2 atmosphere for 24 h, the viable cell number was determined with a cell counting kit-8 from DOJINDO Laboratories, Kumamoto, Japan. </p></sec><sec id="sec3dot2dot4-molecules-24-02603"><title>3.2.4. Influenza Growth Inhibition Assay</title><p>After two washes with MEM, MDCK&#x02013;SIAT1 cells were preincubated with an inhibitor at various concentrations in MEM at 37 &#x000b0;C in 5% CO<sub>2</sub> atmosphere for 1 h. Influenza virus at a multiplicity of infection of 0.03 was pretreated with the same inhibitor at the same concentrations in MEM with 2 &#x003bc;g/mL acetylated trypsin at 4 &#x000b0;C for 1 h. The inhibitor-containing MEM medium on the cells was replaced with the influenza virus-inhibitor mixture. After incubation at 37 &#x000b0;C in a 5% CO<sub>2</sub> atmosphere for 19&#x02013;20 h, the medium was removed. Immediately, the infected cells were fixed and permeabilized with methanol. After two washes, the permeabilized cells were stained with primary antiviral NP mouse antibody (4E6) and secondary &#x003b2;-galactosidase-conjugated antimouse IgG antibody. The number of influenza virus-produced nucleoproteins (NPs) in the permeabilized cells in each well was determined by a galactosidase-based fluorescent assay, as previously described [<xref rid="B26-molecules-24-02603" ref-type="bibr">26</xref>]. A percentage of the fluorescent intensity of each well relative to the fluorescent intensity of the no-inhibitor control well that contained only the virus was used to express the number of influenza virus-produced NPs in each well. Then, a graph was generated by plotting the percentage of relative numbers of influenza virus-produced NPs against the logarithm of the inhibitor concentrations. After fitting the points on the graph through Prism&#x02019;s nonlinear regression analysis, the inhibitor concentration that inhibited virus multiplication by 50% in comparison to the control (IC<sub>50</sub>) was obtained. The influenza virus-produced NPs in the permeabilized cells in each well were visualized as a blue color by a peroxidase-based chromogenic assay [<xref rid="B40-molecules-24-02603" ref-type="bibr">40</xref>].</p></sec></sec></sec><sec sec-type="conclusions" id="sec4-molecules-24-02603"><title>4. Conclusions</title><p>Thus, we developed EdAP, a new 4&#x02032;-ethynyl-2&#x02032;-deoxyadenosine 5&#x02032;-monophosphate analog, as a potent influenza A inhibitor with an IC<sub>50</sub> of 3.8 &#x003bc;M. EdAP was designed based on the results of the anti-influenza activities of several 4&#x02032;-ethynyl-adenosine derivatives. The obtained observations could provide helpful information for developing new anti-influenza nucleosides.</p></sec></body><back><fn-group><fn><p><bold>Sample Availability:</bold> Samples of the compounds are available from the authors.</p></fn></fn-group><app-group><app id="app1-molecules-24-02603"><title>Supplementary Materials</title><p>The spectra of <sup>1</sup>H of compounds <bold>5</bold>, <bold>7</bold>, and <bold>9</bold>&#x02013;<bold>18</bold> and the <sup>13</sup>C-NMR of compounds <bold>5</bold>, <bold>7</bold>, and <bold>9</bold>&#x02013;<bold>17</bold> are available online.</p><supplementary-material content-type="local-data" id="molecules-24-02603-s001"><media xlink:href="molecules-24-02603-s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>T.T., A.S., and E.H. performed the syntheses; N.S. analyzed anti-influenza activities and cytotoxicity; T.T. and S.K. conceived of and designed the synthetic experiments; Y.S., O.H., and F.S. supervised and evaluated the synthetic and biological studies. Writing&#x02014;original draft, T.T.; writing&#x02014;review and editing, N.S., S.K., Y.S., H.O., and F.S.</p></notes><notes><title>Funding</title><p>This research received no external funding.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>There are no conflicts to declare.</p></notes><ref-list><title>References</title><ref id="B1-molecules-24-02603"><label>1.</label><element-citation publication-type="book"><source>Global Influenza Strategy 2019&#x02013;2030</source><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2019</year></element-citation></ref><ref id="B2-molecules-24-02603"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stevaert</surname><given-names>A.</given-names></name><name><surname>Naesens</surname><given-names>L.</given-names></name></person-group><article-title>The influenza virus polymerase complex: An update on its structure, functions, and significance for antiviral drug design</article-title><source>Med. Res. Rev.</source><year>2016</year><volume>36</volume><fpage>1127</fpage><lpage>1173</lpage><pub-id pub-id-type="doi">10.1002/med.21401</pub-id><?supplied-pmid 27569399?><pub-id pub-id-type="pmid">27569399</pub-id></element-citation></ref><ref id="B3-molecules-24-02603"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laborda</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>S.-Y.</given-names></name><name><surname>Voglmeir</surname><given-names>J.</given-names></name></person-group><article-title>Influenza Neuraminidase Inhibitors: Synthetic Approaches, Derivatives and Biological Activity</article-title><source>Molecules</source><year>2016</year><volume>21</volume><elocation-id>1513</elocation-id><pub-id pub-id-type="doi">10.3390/molecules21111513</pub-id><?supplied-pmid 27845731?><pub-id pub-id-type="pmid">27845731</pub-id></element-citation></ref><ref id="B4-molecules-24-02603"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>K.</given-names></name></person-group><article-title>Antivirals Targeting Influenza A Virus</article-title><source>J. Med. Chem.</source><year>2012</year><volume>14</volume><fpage>6263</fpage><lpage>6277</lpage><pub-id pub-id-type="doi">10.1021/jm300455c</pub-id><?supplied-pmid 22612288?><pub-id pub-id-type="pmid">22612288</pub-id></element-citation></ref><ref id="B5-molecules-24-02603"><label>5.</label><element-citation publication-type="patent"><person-group person-group-type="author"><name><surname>Kohgo</surname><given-names>S.</given-names></name><name><surname>Ohrui</surname><given-names>H.</given-names></name><name><surname>Kodama</surname><given-names>E.</given-names></name><name><surname>Matsuoka</surname><given-names>M.</given-names></name><name><surname>Mitsuya</surname><given-names>H.</given-names></name></person-group><article-title>4&#x02032;-c-Substituted-2-Haloadenosine Derivative</article-title><source>U.S. Patent</source><patent>2502199</patent><day>4</day><month>3</month><year>2005</year></element-citation></ref><ref id="B6-molecules-24-02603"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohgo</surname><given-names>S.</given-names></name><name><surname>Yamada</surname><given-names>K.</given-names></name><name><surname>Kitano</surname><given-names>K.</given-names></name><name><surname>Iwai</surname><given-names>Y.</given-names></name><name><surname>Sakata</surname><given-names>S.</given-names></name><name><surname>Ashida</surname><given-names>N.</given-names></name><name><surname>Hayakawa</surname><given-names>H.</given-names></name><name><surname>Nameki</surname><given-names>D.</given-names></name><name><surname>Kodama</surname><given-names>E.</given-names></name><name><surname>Matsupka</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Design, efficient synthesis, and anti-HIV activity of 4&#x02032;-<italic>C</italic>-cyano- and 4&#x02032;-<italic>C</italic>-ethynyl-2&#x02032;-deoxy purine nucleosides</article-title><source>Nucleosides Nucleotides Nucleic Acids</source><year>2004</year><volume>23</volume><fpage>671</fpage><lpage>690</lpage><pub-id pub-id-type="doi">10.1081/NCN-120037508</pub-id><?supplied-pmid 15200030?><pub-id pub-id-type="pmid">15200030</pub-id></element-citation></ref><ref id="B7-molecules-24-02603"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohrui</surname><given-names>H.</given-names></name></person-group><article-title>2&#x02032;-deoxy-4&#x02032;-C-ethynyl-2-fluoroadenosine, a nucleoside reverse transcriptase inhibitor, is highly potent against all human immunodeficiency viruses type 1 and has low toxicity</article-title><source>Chem. Rec.</source><year>2006</year><volume>6</volume><fpage>133</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1002/tcr.20078</pub-id><?supplied-pmid 16795005?><pub-id pub-id-type="pmid">16795005</pub-id></element-citation></ref><ref id="B8-molecules-24-02603"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohrui</surname><given-names>H.</given-names></name><name><surname>Hayakawa</surname><given-names>H.</given-names></name><name><surname>Kohgo</surname><given-names>S.</given-names></name><name><surname>Matsuoka</surname><given-names>M.</given-names></name><name><surname>Kodama</surname><given-names>E.</given-names></name><name><surname>Mitsuya</surname><given-names>H.</given-names></name></person-group><article-title>Creation of Low Toxic Reverse-transcriptase Inhibitory Nucleosides that Prevent the Emergence of Drug-resistant HIV Variants</article-title><source>J. Synth. Org. Chem. Jpn.</source><year>2006</year><volume>64</volume><fpage>716</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.5059/yukigoseikyokaishi.64.716</pub-id></element-citation></ref><ref id="B9-molecules-24-02603"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohrui</surname><given-names>H.</given-names></name><name><surname>Kohgo</surname><given-names>S.</given-names></name><name><surname>Hayakawa</surname><given-names>H.</given-names></name><name><surname>Kodama</surname><given-names>E.</given-names></name><name><surname>Matsuoka</surname><given-names>M.</given-names></name><name><surname>Nakata</surname><given-names>T.</given-names></name><name><surname>Mitsuya</surname><given-names>H.</given-names></name></person-group><article-title>2&#x02032;-deoxy-4&#x02032;-<italic>C</italic>-ethynyl-2-fluoroadenosine: A nucleoside reverse transcriptase inhibitor with highly potent activity against wide spectrum of HIV-1 strains, favorable toxic profiles, and stability in plasma</article-title><source>Nucleosides Nucleotides Nucleic Acids</source><year>2007</year><volume>26</volume><fpage>1543</fpage><lpage>1546</lpage><pub-id pub-id-type="doi">10.1080/15257770701545218</pub-id><?supplied-pmid 18066823?><pub-id pub-id-type="pmid">18066823</pub-id></element-citation></ref><ref id="B10-molecules-24-02603"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michailidis</surname><given-names>E.</given-names></name><name><surname>Marchand</surname><given-names>B.</given-names></name><name><surname>Kodama</surname><given-names>E.</given-names></name><name><surname>Singh</surname><given-names>K.</given-names></name><name><surname>Matsuoka</surname><given-names>M.</given-names></name><name><surname>Kirby</surname><given-names>K.A.</given-names></name><name><surname>Ryan</surname><given-names>E.M.</given-names></name><name><surname>Sawani</surname><given-names>A.M.</given-names></name><name><surname>Nagy</surname><given-names>E.</given-names></name><name><surname>Ashida</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Mechanism of inhibition of HIV-1 reverse transcriptase by 4&#x02032;-Ethynyl-2-fluoro-2&#x02032;-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor</article-title><source>J. Biol. Chem.</source><year>2009</year><volume>284</volume><fpage>35681</fpage><lpage>35691</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.036616</pub-id><?supplied-pmid 19837673?><pub-id pub-id-type="pmid">19837673</pub-id></element-citation></ref><ref id="B11-molecules-24-02603"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohrui</surname><given-names>H.</given-names></name></person-group><article-title>Development of modified nucleosides that have supremely high anti-HIV activity and low toxicity and prevent the emergence of resistant HIV mutants</article-title><source>Proc. Jpn. Acad. Ser. B</source><year>2011</year><volume>87</volume><fpage>53</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.2183/pjab.87.53</pub-id><?supplied-pmid 21422739?><pub-id pub-id-type="pmid">21422739</pub-id></element-citation></ref><ref id="B12-molecules-24-02603"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michailidis</surname><given-names>E.</given-names></name><name><surname>Huber</surname><given-names>A.D.</given-names></name><name><surname>Ryan</surname><given-names>E.M.</given-names></name><name><surname>Ong</surname><given-names>Y.T.</given-names></name><name><surname>Leslie</surname><given-names>M.D.</given-names></name><name><surname>Matzek</surname><given-names>K.B.</given-names></name><name><surname>Singh</surname><given-names>K.</given-names></name><name><surname>Marchand</surname><given-names>B.</given-names></name><name><surname>Hagedorn</surname><given-names>A.N.</given-names></name><name><surname>Kirby</surname><given-names>K.A.</given-names></name><etal/></person-group><article-title>4&#x02032;-Ethynyl-2-fluoro-2&#x02032;-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms</article-title><source>J. Biol. Chem.</source><year>2014</year><volume>289</volume><fpage>24533</fpage><lpage>24548</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.562694</pub-id><?supplied-pmid 24970894?><pub-id pub-id-type="pmid">24970894</pub-id></element-citation></ref><ref id="B13-molecules-24-02603"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kodama</surname><given-names>E.</given-names></name><name><surname>Kohgo</surname><given-names>S.</given-names></name><name><surname>Kitano</surname><given-names>K.</given-names></name><name><surname>Machida</surname><given-names>H.</given-names></name><name><surname>Gatanaga</surname><given-names>H.</given-names></name><name><surname>Shigeta</surname><given-names>S.</given-names></name><name><surname>Matsuoka</surname><given-names>M.</given-names></name><name><surname>Ohrui</surname><given-names>H.</given-names></name><name><surname>Mitsuya</surname><given-names>H.</given-names></name></person-group><article-title>4&#x02032;-Ethynyl nucleoside analogs: Potent inhibitors of multidrug-resistant human immunodeficiency virus variants <italic>in vitro</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>2001</year><volume>45</volume><fpage>1539</fpage><lpage>1546</lpage><pub-id pub-id-type="doi">10.1128/AAC.45.5.1539-1546.2001</pub-id><?supplied-pmid 11302824?><pub-id pub-id-type="pmid">11302824</pub-id></element-citation></ref><ref id="B14-molecules-24-02603"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawamoto</surname><given-names>A.</given-names></name><name><surname>Kodama</surname><given-names>E.</given-names></name><name><surname>Sarafianos</surname><given-names>S.G.</given-names></name><name><surname>Sakagami</surname><given-names>Y.</given-names></name><name><surname>Kohgo</surname><given-names>S.</given-names></name><name><surname>Kitano</surname><given-names>K.</given-names></name><name><surname>Ashida</surname><given-names>N.</given-names></name><name><surname>Iwai</surname><given-names>Y.</given-names></name><name><surname>Hayakawa</surname><given-names>H.</given-names></name><name><surname>Nakata</surname><given-names>H.</given-names></name><etal/></person-group><article-title>2008. 2&#x02032;-Deoxy-4&#x02032;-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants</article-title><source>Int. J. Biochem. Cell Biol.</source><year>2008</year><volume>40</volume><fpage>2410</fpage><lpage>2420</lpage><pub-id pub-id-type="doi">10.1016/j.biocel.2008.04.007</pub-id><?supplied-pmid 18487070?><pub-id pub-id-type="pmid">18487070</pub-id></element-citation></ref><ref id="B15-molecules-24-02603"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michailidis</surname><given-names>E.</given-names></name><name><surname>Ryan</surname><given-names>E.M.</given-names></name><name><surname>Hachiya</surname><given-names>A.</given-names></name><name><surname>Kirby</surname><given-names>K.A.</given-names></name><name><surname>Marchand</surname><given-names>B.</given-names></name><name><surname>Leslie</surname><given-names>M.D.</given-names></name><name><surname>Huber</surname><given-names>A.D.</given-names></name><name><surname>Ong</surname><given-names>Y.T.</given-names></name><name><surname>Jackson</surname><given-names>J.C.</given-names></name><name><surname>Singh</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA</article-title><source>Retrovirology</source><year>2013</year><volume>10</volume><fpage>65</fpage><pub-id pub-id-type="doi">10.1186/1742-4690-10-65</pub-id><?supplied-pmid 23800377?><pub-id pub-id-type="pmid">23800377</pub-id></element-citation></ref><ref id="B16-molecules-24-02603"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maeada</surname><given-names>K.</given-names></name><name><surname>Desai</surname><given-names>D.V.</given-names></name><name><surname>Aoki</surname><given-names>M.</given-names></name><name><surname>Nakata</surname><given-names>H.</given-names></name><name><surname>Kodama</surname><given-names>E.N.</given-names></name><name><surname>Mitsuya</surname><given-names>H.</given-names></name></person-group><article-title>Delayed emergence of HIV-1 variants resistant to 4&#x02032;-ethynyl-2-fluoro-2&#x02032;-deoxyadenosine: Comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001</article-title><source>Antivir. Ther.</source><year>2014</year><volume>19</volume><fpage>179</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.3851/IMP2697</pub-id><?supplied-pmid 24162098?><pub-id pub-id-type="pmid">24162098</pub-id></element-citation></ref><ref id="B17-molecules-24-02603"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>V.H.</given-names></name><name><surname>Smith</surname><given-names>R.A.</given-names></name><name><surname>Masoum</surname><given-names>S.</given-names></name><name><surname>Raugi</surname><given-names>D.N.</given-names></name><name><surname>Ba</surname><given-names>S.</given-names></name><name><surname>Seydi</surname><given-names>M.</given-names></name><name><surname>Grobler</surname><given-names>J.A.</given-names></name><name><surname>Gottlieb</surname><given-names>G.S.</given-names></name></person-group><article-title>MK-8591 (4&#x02032;-ethynyl-2-fluoro-2&#x02032;-deoxyadenosine) exhibits potent activity against HIV-2 isolates and drug-resistant HIV-2 mutants in culture</article-title><source>Antimicrob. Agents Chemother.</source><year>2017</year><volume>61</volume><fpage>e00744-17</fpage><pub-id pub-id-type="doi">10.1128/AAC.00744-17</pub-id><pub-id pub-id-type="pmid">28559249</pub-id></element-citation></ref><ref id="B18-molecules-24-02603"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Njenda</surname><given-names>D.T.</given-names></name><name><surname>Aralaguppe</surname><given-names>S.G.</given-names></name><name><surname>Singh</surname><given-names>K.</given-names></name><name><surname>Rao</surname><given-names>R.</given-names></name><name><surname>S&#x000f6;nnerborg</surname><given-names>A.</given-names></name><name><surname>Sarafianos</surname><given-names>S.G.</given-names></name><name><surname>Neogi</surname><given-names>U.</given-names></name></person-group><article-title>Antiretroviral potency of 4&#x02032;-ethnyl-2&#x02032;-fluoro-2&#x02032;-deoxyadenosine, tenofovir alafenamide and second-generation NNRTIs across diverse HIV-1 subtypes</article-title><source>J. Antimicrob. Chemother.</source><year>2018</year><volume>73</volume><fpage>2721</fpage><lpage>2728</lpage><pub-id pub-id-type="doi">10.1093/jac/dky256</pub-id><?supplied-pmid 30053052?><pub-id pub-id-type="pmid">30053052</pub-id></element-citation></ref><ref id="B19-molecules-24-02603"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takamatsu</surname><given-names>Y.</given-names></name><name><surname>Das</surname><given-names>D.</given-names></name><name><surname>Kohgo</surname><given-names>S.</given-names></name><name><surname>Hayashi</surname><given-names>H.</given-names></name><name><surname>Delino</surname><given-names>N.S.</given-names></name><name><surname>Sarafianos</surname><given-names>S.G.</given-names></name><name><surname>Mitsuya</surname><given-names>H.</given-names></name><name><surname>Maeda</surname><given-names>K.</given-names></name></person-group><article-title>The High Genetic Barrier of EFdA/MK-8591 Stems from Strong Interactions with the Active Site of Drug-Resistant HIV-1 Reverse Transcriptase</article-title><source>Cell Chem. Biol.</source><year>2018</year><volume>25</volume><fpage>1268</fpage><lpage>1278</lpage><pub-id pub-id-type="pmid">30174310</pub-id></element-citation></ref><ref id="B20-molecules-24-02603"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphey-Corb</surname><given-names>M.</given-names></name><name><surname>Rajakumar</surname><given-names>P.</given-names></name><name><surname>Michael</surname><given-names>H.</given-names></name><name><surname>Nyaundi</surname><given-names>J.</given-names></name><name><surname>Didier</surname><given-names>P.J.</given-names></name><name><surname>Reeve</surname><given-names>A.B.</given-names></name><name><surname>Mitsuya</surname><given-names>H.</given-names></name><name><surname>Sarafianos</surname><given-names>S.G.</given-names></name><name><surname>Parniak</surname><given-names>M.A.</given-names></name></person-group><article-title>Response of simian immunodeficiency virus to the novel nucleoside reverse transcriptase inhibitor 4&#x02032;-ethynyl-2-fluoro-2&#x02032;-deoxyadenosine in vitro and in vivo</article-title><source>Antimicrob. Agents Chemother.</source><year>2012</year><volume>56</volume><fpage>4707</fpage><lpage>4712</lpage><pub-id pub-id-type="doi">10.1128/AAC.00723-12</pub-id><pub-id pub-id-type="pmid">22713337</pub-id></element-citation></ref><ref id="B21-molecules-24-02603"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hachiya</surname><given-names>A.</given-names></name><name><surname>Reeve</surname><given-names>A.B.</given-names></name><name><surname>Marchand</surname><given-names>B.</given-names></name><name><surname>Michailidis</surname><given-names>E.</given-names></name><name><surname>Ong</surname><given-names>Y.T.</given-names></name><name><surname>Kirby</surname><given-names>K.A.</given-names></name><name><surname>Leslie</surname><given-names>M.D.</given-names></name><name><surname>Oka</surname><given-names>S.</given-names></name><name><surname>Kodama</surname><given-names>E.N.</given-names></name><name><surname>Rohan</surname><given-names>L.C.</given-names></name><etal/></person-group><article-title>Evaluation of combinations of 4&#x02032;-ethynyl-2-fluoro-2&#x02032;-deoxyadenosine with clinically used antiretroviral drugs</article-title><source>Antimicrob. Agents Chemother.</source><year>2013</year><volume>57</volume><fpage>4554</fpage><lpage>4558</lpage><pub-id pub-id-type="doi">10.1128/AAC.00283-13</pub-id><pub-id pub-id-type="pmid">23796932</pub-id></element-citation></ref><ref id="B22-molecules-24-02603"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Parniak</surname><given-names>M.A.</given-names></name><name><surname>Mitsuya</surname><given-names>H.</given-names></name><name><surname>Sarafianos</surname><given-names>S.G.</given-names></name><name><surname>Graebing</surname><given-names>P.W.</given-names></name><name><surname>Rohan</surname><given-names>L.C.</given-names></name></person-group><article-title>Preformulation studies of EFdA, a novel nucleoside reverse transcriptase inhibitor for HIV prevention</article-title><source>Drug Dev. Ind. Pharm.</source><year>2014</year><volume>40</volume><fpage>1101</fpage><lpage>1111</lpage><pub-id pub-id-type="doi">10.3109/03639045.2013.809535</pub-id><pub-id pub-id-type="pmid">23841536</pub-id></element-citation></ref><ref id="B23-molecules-24-02603"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoddart</surname><given-names>C.A.</given-names></name><name><surname>Galkina</surname><given-names>S.A.</given-names></name><name><surname>Joshi</surname><given-names>P.</given-names></name><name><surname>Kosikova</surname><given-names>G.</given-names></name><name><surname>Moreno</surname><given-names>M.E.</given-names></name><name><surname>Rivera</surname><given-names>J.M.</given-names></name><name><surname>Sloan</surname><given-names>B.</given-names></name><name><surname>Reeve</surname><given-names>A.B.</given-names></name><name><surname>Sarafianos</surname><given-names>S.G.</given-names></name><name><surname>Murphey-Corb</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Oral administration of the nucleoside EFdA (4&#x02032;-ethynyl-2-fluoro-2&#x02032;-deoxyadenosine) provides rapid suppression of HIV viremia in humanized mice and favorable pharmacokinetic properties in mice and the rhesus macaque</article-title><source>Antimicrob. Agents Chemother.</source><year>2015</year><volume>59</volume><fpage>4190</fpage><lpage>4198</lpage><pub-id pub-id-type="doi">10.1128/AAC.05036-14</pub-id><pub-id pub-id-type="pmid">25941222</pub-id></element-citation></ref><ref id="B24-molecules-24-02603"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Markowitz</surname><given-names>M.</given-names></name><name><surname>Sarafianos</surname><given-names>S.G.</given-names></name></person-group><article-title>4&#x02032;-Ethynyl-2-fluoro-2&#x02032;-deoxyadenosine, MK-8591: A novel HIV-1 reverse transcriptase translocation inhibitor</article-title><source>Curr. Opin. HIV AIDS</source><year>2018</year><volume>13</volume><fpage>294</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1097/COH.0000000000000467</pub-id><?supplied-pmid 29697468?><pub-id pub-id-type="pmid">29697468</pub-id></element-citation></ref><ref id="B25-molecules-24-02603"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohrui</surname><given-names>H.</given-names></name><name><surname>Kohgo</surname><given-names>S.</given-names></name><name><surname>Kitano</surname><given-names>K.</given-names></name><name><surname>Sakata</surname><given-names>S.</given-names></name><name><surname>Kodama</surname><given-names>E.</given-names></name><name><surname>Yoshimura</surname><given-names>K.</given-names></name><name><surname>Matsuoka</surname><given-names>M.</given-names></name><name><surname>Shigeta</surname><given-names>S.</given-names></name><name><surname>Mitsuya</surname><given-names>H.</given-names></name></person-group><article-title>Syntheses of 4&#x02032;-C-ethynyl-beta-D-arabino- and 4&#x02032;-C-ethynyl-2&#x02032;-deoxy-beta-D-ribo- pentofuranosylpyrimidines and -purines and evaluation of their anti-HIV activity</article-title><source>J. Med. Chem.</source><year>2000</year><volume>43</volume><fpage>4516</fpage><lpage>4525</lpage><pub-id pub-id-type="doi">10.1021/jm000209n</pub-id><?supplied-pmid 11087576?><pub-id pub-id-type="pmid">11087576</pub-id></element-citation></ref><ref id="B26-molecules-24-02603"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sriwilaijaroen</surname><given-names>N.</given-names></name><name><surname>Wilairat</surname><given-names>P.</given-names></name><name><surname>Hiramatsu</surname><given-names>H.</given-names></name><name><surname>Takahashi</surname><given-names>T.</given-names></name><name><surname>Suzuki</surname><given-names>T.</given-names></name><name><surname>Ito</surname><given-names>M.</given-names></name><name><surname>Ito</surname><given-names>Y.</given-names></name><name><surname>Tashiro</surname><given-names>M.</given-names></name><name><surname>Suzuki</surname><given-names>Y.</given-names></name></person-group><article-title>Mechanisms of the action of povidone-iodine against human and avian influenza A viruses: Its effects on hemagglutination and sialidase activities</article-title><source>Virol. J.</source><year>2009</year><volume>6</volume><fpage>124</fpage><pub-id pub-id-type="doi">10.1186/1743-422X-6-124</pub-id><?supplied-pmid 19678928?><pub-id pub-id-type="pmid">19678928</pub-id></element-citation></ref><ref id="B27-molecules-24-02603"><label>27.</label><element-citation publication-type="patent"><person-group person-group-type="author"><name><surname>Sugawara</surname><given-names>F.</given-names></name><name><surname>Takeuchi</surname><given-names>T.</given-names></name><name><surname>Kamisuki</surname><given-names>S.</given-names></name><name><surname>Ohrui</surname><given-names>H.</given-names></name><name><surname>Suzuki</surname><given-names>Y.</given-names></name></person-group><article-title>Japanese Kokai Tokkyo Koho</article-title><source>JP Patent</source><patent>2015,151,346 A</patent><day>12</day><season>February </season><year>2015</year></element-citation></ref><ref id="B28-molecules-24-02603"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meier</surname><given-names>C.</given-names></name></person-group><article-title>2-Nucleos-5&#x02032;-<italic>O</italic>-yl-4H-1,3,2-benzodioxaphos-phinin-2-oxides&#x02014;A new concept for lipophilic, potential prodrugs of biologically active nucleoside monophosphates</article-title><source>Angew. Chem. Int. Ed. Engl.</source><year>1996</year><volume>35</volume><fpage>70</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1002/anie.199600701</pub-id></element-citation></ref><ref id="B29-molecules-24-02603"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meier</surname><given-names>C.</given-names></name><name><surname>Knispel</surname><given-names>T.</given-names></name><name><surname>Clercq</surname><given-names>E.D.</given-names></name><name><surname>Balzarini</surname><given-names>J.</given-names></name></person-group><article-title>cycloSal-Pronucleotides of 2&#x02032;,3&#x02032;-dideoxyadenosine and 2&#x02032;, 3&#x02032;-dideoxy-2&#x02032;,3&#x02032;-didehydroadenosine: Synthesis and antiviral evaluation of a highly efficient nucleotide delivery system</article-title><source>J. Med. Chem.</source><year>1999</year><volume>42</volume><fpage>1604</fpage><lpage>1614</lpage><pub-id pub-id-type="doi">10.1021/jm981096z</pub-id><?supplied-pmid 10229629?><pub-id pub-id-type="pmid">10229629</pub-id></element-citation></ref><ref id="B30-molecules-24-02603"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meier</surname><given-names>C.</given-names></name><name><surname>Balzarini</surname><given-names>J.</given-names></name></person-group><article-title>Application of the cycloSal-prodrug approach for improving the biological potential of phosphorylated biomolecules</article-title><source>Antoviral Res.</source><year>2006</year><volume>71</volume><fpage>282</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2006.04.011</pub-id><?supplied-pmid 16735066?><pub-id pub-id-type="pmid">16735066</pub-id></element-citation></ref><ref id="B31-molecules-24-02603"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamaguchi</surname><given-names>R.</given-names></name><name><surname>Imanishi</surname><given-names>T.</given-names></name><name><surname>Kohgo</surname><given-names>S.</given-names></name><name><surname>Horie</surname><given-names>H.</given-names></name><name><surname>Ohrui</surname><given-names>H.</given-names></name></person-group><article-title>Synthesis of 4&#x02032;-C-ethynyl-&#x003b2;-D-ribo-pentofuranosyl pyrimidines</article-title><source>Biosci. Biotechnol. Biochem.</source><year>1999</year><volume>63</volume><fpage>736</fpage><lpage>742</lpage><pub-id pub-id-type="doi">10.1271/bbb.63.736</pub-id><?supplied-pmid 27389104?><pub-id pub-id-type="pmid">27389104</pub-id></element-citation></ref><ref id="B32-molecules-24-02603"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corey</surname><given-names>E.J.</given-names></name><name><surname>Fuchs</surname><given-names>P.L.</given-names></name></person-group><article-title>A synthetic method for formyl&#x02192;ethynyl conversion (RCHO&#x02192;RC&#x02261;CH or RC&#x02261;CR&#x02032;)</article-title><source>Tetrahedron Lett.</source><year>1972</year><volume>36</volume><fpage>3769</fpage><lpage>3772</lpage><pub-id pub-id-type="doi">10.1016/S0040-4039(01)94157-7</pub-id></element-citation></ref><ref id="B33-molecules-24-02603"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leonard</surname><given-names>N.J.</given-names></name><name><surname>Laursen</surname><given-names>R.A.</given-names></name></person-group><article-title>The synthesis of 3-&#x003b2;-<sc>d</sc>-ribofuranosyladenine</article-title><source>J. Am. Chem. Soc.</source><year>1963</year><volume>85</volume><fpage>2026</fpage><lpage>2028</lpage><pub-id pub-id-type="doi">10.1021/ja00896a036</pub-id></element-citation></ref><ref id="B34-molecules-24-02603"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leonard</surname><given-names>N.J.</given-names></name><name><surname>Laursen</surname><given-names>R.A.</given-names></name></person-group><article-title>Synthesis of 3-&#x003b2;-<sc>d</sc>-ribofuranosyladenine and (3-&#x003b2;-<sc>d</sc>-ribofuranosyladenine)-5&#x02032;-phosphate</article-title><source>Biochemistry</source><year>1965</year><volume>4</volume><fpage>354</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1021/bi00878a027</pub-id></element-citation></ref><ref id="B35-molecules-24-02603"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barton</surname><given-names>D.H.R.</given-names></name><name><surname>McCombie</surname><given-names>S.W.</given-names></name></person-group><article-title>A new method for the deoxygenation of secondary alcohols</article-title><source>J. Chem. Soc. Perkin. Trans.</source><year>1975</year><volume>1</volume><fpage>1574</fpage><lpage>1585</lpage><pub-id pub-id-type="doi">10.1039/p19750001574</pub-id></element-citation></ref><ref id="B36-molecules-24-02603"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crich</surname><given-names>D.</given-names></name><name><surname>Quintero</surname><given-names>L.</given-names></name></person-group><article-title>Radical chemistry associated with the thiocarbonyl group</article-title><source>Chem. Rev.</source><year>1989</year><volume>89</volume><fpage>1413</fpage><lpage>1432</lpage><pub-id pub-id-type="doi">10.1021/cr00097a001</pub-id></element-citation></ref><ref id="B37-molecules-24-02603"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayakawa</surname><given-names>H.</given-names></name><name><surname>Kohgo</surname><given-names>S.</given-names></name><name><surname>Kitano</surname><given-names>K.</given-names></name><name><surname>Ashida</surname><given-names>N.</given-names></name><name><surname>Kodama</surname><given-names>E.</given-names></name><name><surname>Mitsuya</surname><given-names>H.</given-names></name><name><surname>Ohrui</surname><given-names>H.</given-names></name></person-group><article-title>Potential of 4&#x02032;-<italic>C</italic>-substituted nucleosides for the treatment of HIV-1</article-title><source>Antivir. Chem. Chemother.</source><year>2004</year><volume>15</volume><fpage>169</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1177/095632020401500401</pub-id><?supplied-pmid 15457679?><pub-id pub-id-type="pmid">15457679</pub-id></element-citation></ref><ref id="B38-molecules-24-02603"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sriwilaijaroen</surname><given-names>N.</given-names></name><name><surname>Kadowaki</surname><given-names>A.</given-names></name><name><surname>Onishi</surname><given-names>Y.</given-names></name><name><surname>Gato</surname><given-names>N.</given-names></name><name><surname>Ujike</surname><given-names>M.</given-names></name><name><surname>Odagiri</surname><given-names>T.</given-names></name><name><surname>Tashiro</surname><given-names>M.</given-names></name><name><surname>Suzuki</surname><given-names>Y.</given-names></name></person-group><article-title>Mumefural and related HMF derivatives from Japanese apricot fruit juice concentrate show multiple inhibitory effects on pandemic influenza A (H1N1) virus</article-title><source>Food Chem.</source><year>2011</year><volume>127</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.foodchem.2010.12.031</pub-id></element-citation></ref><ref id="B39-molecules-24-02603"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sriwilaijaroen</surname><given-names>N.</given-names></name><name><surname>Magesh</surname><given-names>S.</given-names></name><name><surname>Imamura</surname><given-names>A.</given-names></name><name><surname>Ando</surname><given-names>H.</given-names></name><name><surname>Ishida</surname><given-names>H.</given-names></name><name><surname>Sakai</surname><given-names>M.</given-names></name><name><surname>Ishitsubo</surname><given-names>E.</given-names></name><name><surname>Hori</surname><given-names>T.</given-names></name><name><surname>Moriya</surname><given-names>S.</given-names></name><name><surname>Ishikawa</surname><given-names>T.</given-names></name><etal/></person-group><article-title>A novel potent and highly specific inhibitor against influenza viral N1-N9 neuraminidases: Insight into neuraminidase-inhibitor interactions</article-title><source>J. Med. Chem.</source><year>2016</year><volume>59</volume><fpage>4563</fpage><lpage>4577</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b01863</pub-id><?supplied-pmid 27095056?><pub-id pub-id-type="pmid">27095056</pub-id></element-citation></ref><ref id="B40-molecules-24-02603"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sriwilaijaroen</surname><given-names>N.</given-names></name><name><surname>Suzuki</surname><given-names>K.</given-names></name><name><surname>Takashita</surname><given-names>E.</given-names></name><name><surname>Hiramatsu</surname><given-names>H.</given-names></name><name><surname>Kanie</surname><given-names>O.</given-names></name><name><surname>Suzuki</surname><given-names>Y.</given-names></name></person-group><article-title>6SLN-lipo PGA specifically catches (coats) human influenza virus and synergizes neuraminidase-targeting drugs for human influenza therapeutic potential</article-title><source>J. Antimicrob. Chemother.</source><year>2015</year><volume>70</volume><fpage>2797</fpage><lpage>2809</lpage><pub-id pub-id-type="doi">10.1093/jac/dkv193</pub-id><pub-id pub-id-type="pmid">26169554</pub-id></element-citation></ref></ref-list><sec sec-type="display-objects"><title>Figures, Scheme and Table</title><fig id="molecules-24-02603-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Structures of 4&#x02032;-ethynyl-2-fluoro-2&#x02032;-deoxyadenosine (EFdA) (<bold>1</bold>), 4&#x02032;-ethynyl-2&#x02032;-deoxyadenosine (EdA) (<bold>2</bold>), and 4&#x02032;-ethynyl-2-fluoroadenosine (EA) (<bold>3</bold>).</p></caption><graphic xlink:href="molecules-24-02603-g001"/></fig><fig id="molecules-24-02603-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Structures of EFdAP (<bold>4</bold>) and EdAP (<bold>5</bold>).</p></caption><graphic xlink:href="molecules-24-02603-g002"/></fig><fig id="molecules-24-02603-sch001" orientation="portrait" position="float"><object-id pub-id-type="pii">molecules-24-02603-sch001_Scheme 1</object-id><label>Scheme 1</label><caption><p>Synthesis of EdAP (<bold>5</bold>).</p></caption><graphic xlink:href="molecules-24-02603-sch001"/></fig><fig id="molecules-24-02603-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Inhibition of the influenza virus growth in the MDCK&#x02013;SIAT1 cells by EdAP (<bold>5</bold>). Upper panel: The number of influenza virus-produced nucleoproteins (NPs) in cells decreased with an increase in EdAP concentration, as indicated. Lower panel: The reduction in the relative numbers of influenza virus-produced NPs in cells was a function of EdAP (filled circle and solid line) or oseltamivir carboxylate (open square and dashed line) concentrations, as indicated.</p></caption><graphic xlink:href="molecules-24-02603-g003"/></fig><table-wrap id="molecules-24-02603-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">molecules-24-02603-t001_Table 1</object-id><label>Table 1</label><caption><p>The anti-influenza and cytotoxicity of compounds <bold>1</bold>&#x02013;<bold>3</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">H1N1 Influenza A Virus</th><th align="center" valign="top" style="border-top:solid thin" rowspan="1" colspan="1">MDCK&#x02013;SIAT1</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Compound</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC<sub>50</sub> (&#x003bc;M)</th><th align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">CC<sub>50</sub>
<sup>1</sup> (&#x003bc;M) </th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>1</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">63</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003e;1000</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>2</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">401</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003e;1000</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>3</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;1000</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;1000</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> The cell counting kit-8 (CCK8) assay was used. IC<sub>50</sub>: 50% inhibitory concentration. CC<sub>50</sub>: 50% cytotoxic concentration. MDCK&#x02013;SIAT1: Madin&#x02013;Darby canine kidney cells transfected with human &#x003b1;2-6-sialyltransferase (SIAT1) cDNA.</p></fn></table-wrap-foot></table-wrap></sec></back></article>